2012年8月20日 讯 /生物谷BIOON/ --在一项新研究中，研究人员发现B型流感病毒高度保守性的抗原表位，为流感的防治带来新的希望。
在这项研究中，研究人员发现广泛性中和B型流感病毒的抗体，为研发基于流感单克隆抗体的免疫疗法和"万能"流感疫苗带来了希望。然而，每年流感疫情当中大多数，是由两种共同传播的但抗原性不同的B型流感病毒造成的。
当前的这项研究发现人类单克隆抗体：CR8033，CR8071，CR9114，可保护小鼠免受上述两种致命性B型流感病毒的伤害。CR8033和CR8071抗体识别B型流感病毒血凝素（HA）头部区域不同的保守性抗原表位，而CR9114结合一个位于HA茎部的保守性抗原表位，从而防止流感A和B型流感病毒对机体的致命毒害。
这些抗体可能预示着，人们在开发基于单克隆抗体的流感治疗方法和针对所有A和B型流感病毒的通用流感疫苗方面取得重大进展。（生物谷bioon.com）
doi:10.1016/j.cell.2011.10.017
PMC:
PMID:
Highly Conserved Protective Epitopes on Influenza B Viruses
Cyrille Dreyfus1,*,Nick S. Laursen1,2,*,Ted Kwaks3,David Zuijdgeest3,Reza Khayat1,Damian C. Ekiert1,?,Jeong Hyun Lee1,Zoltan Metlagel1,?,Miriam V. Bujny3,Mandy Jongeneelen3,Remko van der Vlugt3,Mohammed Lamrani3,Hans J. W. M. Korse3,Eric Geelen3,?zcan Sahin3,Martijn Sieuwerts3,Just P. J. Brakenhoff3,Ronald Vogels3,Olive T. W. Li4,Leo L. M. Poon4,Malik Peiris4,Wouter Koudstaal3,Andrew B. Ward1,Ian A. Wilson1,5,§,Jaap Goudsmit3,§,Robert H. E. Friesen
Identification of broadly neutralizing antibodies against influenza A viruses has raised hopes for the development of monoclonal antibody–based immunotherapy and “universal” vaccines for influenza. However, a significant part of the annual flu burden is caused by two cocirculating, antigenically distinct lineages of influenza B viruses. Here, we report human monoclonal antibodies, CR8033, CR8071, and CR9114, that protect mice against lethal challenge from both lineages. Antibodies CR8033 and CR8071 recognize distinct conserved epitopes in the head region of the influenza B hemagglutinin (HA), whereas CR9114 binds a conserved epitope in the HA stem and protects against lethal challenge with influenza A and B viruses. These antibodies may inform on development of monoclonal antibody–based treatments and a universal flu vaccine for all influenza A and B viruses.
